111 131

Cited 15 times in

Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort

Authors
 Minkyu Jung  ;  Jeeyun Lee  ;  Tae Min Kim  ;  Dae Ho Lee  ;  Jin Hyung Kang  ;  Sung Young Oh  ;  Soo Jung Lee  ;  Sang Joon Shin 
Citation
 CANCER RESEARCH AND TREATMENT, Vol.49(1) : 44-53, 2017 
Journal Title
 CANCER RESEARCH AND TREATMENT 
ISSN
 1598-2998 
Issue Date
2017
MeSH
Aged ; Antineoplastic Agents, Immunological/administration & dosage ; Antineoplastic Agents, Immunological/adverse effects ; Antineoplastic Agents, Immunological/therapeutic use* ; Biomarkers ; Cohort Studies ; Female ; Humans ; Ipilimumab/administration & dosage ; Ipilimumab/adverse effects ; Ipilimumab/therapeutic use* ; Kaplan-Meier Estimate ; Male ; Melanoma/diagnosis ; Melanoma/drug therapy* ; Melanoma/mortality ; Middle Aged ; Molecular Targeted Therapy ; Neoplasm Metastasis ; Neoplasm Staging ; Republic of Korea ; Treatment Outcome
Keywords
Biomarkers ; Immunotherapy ; Ipilimumab ; Melanoma
Abstract
PURPOSE: Ipilimumab improves survival in advanced melanoma patients. However, the efficacy and safety of ipilimumab has not been evaluated in Asian melanoma patients with a high frequency of mucosal and acral melanoma subtypes. MATERIALS AND METHODS: Advanced melanoma patients treated with 3 mg/kg ipilimumab in a Korean multicenter named-patient program (NPP) were evaluated between September 2014 and July 2015. Baseline characteristics and blood parameters including neutrophil to lymphocyte ratio (NLR) were assessed, and outcome and adverse events were evaluated according to subtypes. RESULTS: A total of 104 advanced melanoma patients were treated. The primary sites were acral (31.7%), mucosal (26%), cutaneous (26%), uveal (9.6%), and unknown (6.7%). Sixty-eight patients (65.4%) experienced adverse events, and the most common toxicity was skin rash (22.1%), 10 patients (9.6%) experienced adverse events of grade 3 or higher. The median progression-free survival (PFS) was 2.73 months (95% confidence interval, 2.67 to 2.85), and there was no difference in PFS according to subtypes. Poor performance status, liver metastasis, and NLR (≥ 5) were independent poor prognostic factors by multivariate analysis. CONCLUSION: In the Korean NPP cohort, ipilimumab showed similar efficacy and tolerability compared to Western patients, regardless of subtypes. All subtypes should benefit from ipilimumab with consideration of performance status, liver metastasis, and NLR.
Files in This Item:
T201700149.pdf Download
DOI
10.4143/crt.2016.024
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
Yonsei Authors
Shin, Sang Joon(신상준) ORCID logo https://orcid.org/0000-0001-5350-7241
Jung, Min Kyu(정민규) ORCID logo https://orcid.org/0000-0001-8281-3387
URI
https://ir.ymlib.yonsei.ac.kr/handle/22282913/154108
사서에게 알리기
  feedback

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse